不安障害とうつ病治療の世界市場分析:製品別(抗うつ薬、SSRI、SNRI、ベンゾジアゼピン、装置と治療、TNS、DBS、VBS)、症状別(MDD、OCD、恐怖症)、セグメント予測、2014-2025...市場調査レポートについてご紹介

【英文タイトル】Anxiety Disorders And Depression Treatment Market Analysis By Product (Antidepressant Drugs, SSRIs, SNRIs, Benzodiazepines, Devices And Therapy, TNS, DBS, VBS), By Indication (MDD, OCD, Phobia), And Segment Forecasts, 2014-2025

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents

Chapter 1 Research Methodology & Scope
1.1 Region Wise Market Calculation
1.1.1 Region Wise Market: Base Estimates
1.1.2 Global Market: CAGR Calculation
1.2 Region based segment share calculation
1.3 List of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Anxiety Disorder And Depression Treatment Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.1.1 Market Driver Analysis
3.1.1.1 Increasing prevalence of depression
3.1.1.2 Emergence of novel biologics
3.1.1.3 Increasing awareness level
3.1.2 Market Restraint Analysis
3.1.2.1 Patent expiration of branded drugs
3.2 Penetration & growth prospect mapping
3.3 Anxiety Disorders and Depression Treatment – PESTLE Analysis
3.4 Industry Analysis – Porter’s
Chapter 4 Market Categorization 1: Product Estimates & Trend Analysis
4.1 Anxiety Disorders and Depression Treatment Market: Product Movement Analysis
4.2 Antidepressant Drugs
4.2.1 Antidepressant drugs market, 2014 – 2025 (USD Million)
4.2.2 Selective Serotonin Reuptake Inhibitors (SSRIs)
4.2.2.1 SSRIs market, 2014 – 2025 (USD Million)
4.2.3 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
4.2.3.1 SNRIs market, 2014 – 2025 (USD Million)
4.2.4 Tricyclic Antidepressants (TCAs)
4.2.4.1 TCAs market, 2014 – 2025 (USD Million)
4.2.5 Monoamine Oxidase inhibitors (MAOIs)
4.2.5.1 MAOIs market, 2014 – 2025 (USD Million)
4.2.6 Atypical Antipsychotics
4.2.6.1 Atypical antipsychotics market, 2014 – 2025 (USD Million)
4.2.7 Benzodiazepines
4.2.7.1 Benzodiazepines market, 2014 – 2025 (USD Million)
4.2.8 Anticonvulsants
4.2.8.1 Anticonvulsants market, 2014 – 2025 (USD Million)
4.2.9 Beta-Blockers
4.2.9.1 Beta-Blockers market, 2014 – 2025 (USD Million)
4.2.10 Others
4.2.10.1 Others market, 2014 – 2025 (USD Million)
4.3 Therapy & Devices
4.3.1 Therapy & devices market, 2014 – 2025 (USD Million)
4.3.2 Fisher-Wallace stimulator
4.3.2.1 Fisher-Wallace stimulator market, 2014 – 2025 (USD Million)
4.3.3 Transcranial Magnetic Stimulation (TMS)
4.3.3.1 TMS market, 2014 – 2025 (USD Million)
4.3.4 Deep Brain Stimulation (DBS)
4.3.4.1 DBS market, 2014 – 2025 (USD Million)
4.3.5 Vagus nerve stimulation (VNS)
4.3.5.1 VNS market, 2014 – 2025 (USD Million)
4.3.6 Electroconvulsive Therapy (ECT)
4.3.6.1 ECT market, 2014 – 2025 (USD Million)
4.3.7 Cognitive Behaviour Therapy (CBT)
4.3.7.1 CBT market, 2014 – 2025 (USD Million)
4.3.8 Others
4.3.8.1 Others market, 2014 – 2025 (USD Million)
Chapter 5 Market Categorization 2: Indication Estimates & Trend Analysis
5.1 Anxiety disorders and depression treatment market: indication movement analysis
5.2 Major Depressive Disorder (MDD)
5.2.1 MDD market, 2014 – 2025 (USD Million)
5.3 Obsessive-Compulsive Disorder (OCD)
5.3.1 OCD market, 2014 – 2025 (USD Million)
5.4 Phobia
5.4.1 Phobia market, 2014 – 2025 (USD Million)
5.5 Others
5.5.1 Others market, 2014 – 2025 (USD Million)
Chapter 6 Market Categorization 3: Regional Estimates & Trend Analysis, by Product Type and Indication
6.1 Anxiety Disorders and Depression Treatment market share by region, 2015 & 2025
6.2 North America
6.2.1 North America Anxiety Disorders and Depression Treatment market, 2014 – 2025 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. Anxiety disorders and depression treatment market, 2014 – 2025 (USD Million)
6.2.3 Canada
6.2.3.1 Canada anxiety disorders and depression treatment market, 2014 – 2025 (USD Million)
6.3 Europe
6.3.1 Europe anxiety disorders and depression treatment market, 2014 – 2025 (USD Million)
6.3.2 UK
6.3.2.1 UK anxiety disorders and depression treatment market, 2014 – 2025 (USD Million)
6.3.3 Germany
6.3.3.1 Germany anxiety disorders and depression treatment market, 2014 – 2025 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific anxiety disorders and depression treatment market, 2014 – 2025 (USD Million)
6.4.2 Japan
6.4.2.1 Japan anxiety disorders and depression treatment market, 2014 – 2025 (USD Million)
6.4.3 China
6.4.3.1 China anxiety disorders and depression treatment market, 2014 – 2025 (USD Million)
6.4.4 India
6.4.4.1 India anxiety disorders and depression treatment market, 2014 – 2025 (USD Million)
6.5 Latin America
6.5.1 Latin America anxiety disorders and depression treatment market, 2014 – 2025 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil anxiety disorders and depression treatment market, 2014 – 2025 (USD Million)
6.5.3 Mexico
6.5.3.1 Mexico anxiety disorders and depression treatment market, 2014 – 2025 (USD Million)
6.6 MEA
6.6.1 MEA anxiety disorders and depression treatment market, 2014 – 2025 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa anxiety disorders and depression treatment market, 2014 – 2025 (USD Million)
Chapter 7 Competitive Landscape
7.1 Strategy framework
7.2 Market participation categorization
7.3 Company Profiles
7.3.1 Pfizer Inc,
7.3.1.1 Company Overview
7.3.1.2 Financial Performance
7.3.1.3 Product Benchmarking
7.3.1.4 Strategic Initiatives
7.3.2 GlaxoSmithKline
7.3.2.1 Company Overview
7.3.2.2 Financial Performance
7.3.2.3 Product Benchmarking
7.3.3 Merck & Co. Inc
7.3.3.1 Company Overview
7.3.3.2 Financial Performance
7.3.3.3 Product Benchmarking
7.3.3.4 Strategic Initiatives
7.3.4 AstraZeneca
7.3.4.1 Company Overview
7.3.4.2 Financial Performance
7.3.4.3 Product Benchmarking
7.3.4.4 Strategic Initiatives
7.3.5 Eli Lily & Co
7.3.5.1 Company Overview
7.3.5.2 Financial Performance
7.3.5.3 Product Benchmarking
7.3.5.4 Strategic Initiatives
7.3.6 Johnson & Johnson
7.3.6.1 Company Overview
7.3.6.2 Financial Performance
7.3.6.3 Product Benchmarking
7.3.6.4 Strategic Initiatives
7.3.7 Forest Laboratories, Inc
7.3.7.1 Company Overview
7.3.7.2 Financial Performance
7.3.7.3 Product Benchmarking
7.3.7.4 Strategic Initiatives
7.3.8 Sanofi-Aventis
7.3.8.1 Company Overview
7.3.8.2 Financial Performance
7.3.8.3 Product Benchmarking
7.3.8.4 Strategic Initiatives
7.3.9 H. Lundbeck A/S
7.3.9.1 Company Overview
7.3.9.2 Financial Performance
7.3.9.3 Product Benchmarking
7.3.9.4 Strategic Initiatives
7.3.10 Bristol-Myers Squibb Company
7.3.10.1 Company Overview
7.3.10.2 Financial Performance
7.3.10.3 Product Benchmarking
7.3.10.4 Strategic Initiatives


【レポート販売概要】

■ タイトル:不安障害とうつ病治療の世界市場分析:製品別(抗うつ薬、SSRI、SNRI、ベンゾジアゼピン、装置と治療、TNS、DBS、VBS)、症状別(MDD、OCD、恐怖症)、セグメント予測、2014-2025
■ 英文:Anxiety Disorders And Depression Treatment Market Analysis By Product (Antidepressant Drugs, SSRIs, SNRIs, Benzodiazepines, Devices And Therapy, TNS, DBS, VBS), By Indication (MDD, OCD, Phobia), And Segment Forecasts, 2014-2025
■ 発行日:2016年12月22日
■ 調査会社:Grand View Research
■ 商品コード:GVIEW707061
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。